{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:37:51Z","timestamp":1774471071178,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DigiMed Bayern","award":["DMB-1805\u20130001"],"award-info":[{"award-number":["DMB-1805\u20130001"]}]},{"name":"Deutsches Herzzentrum M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current guideline recommendations for the treatment of coronary in-stent restenosis (ISR) are primarily based on evidence from smaller, randomized trials comparing drug-coated balloons (DCBs) and second-generation drug-eluting stents (DES).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose was to compare clinical outcomes between DCB and DES in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this population-based cohort study, we identified 10,292 patients with ISR who underwent either DCB or DES intervention. After 1:1 propensity score matching, 3942 patients treated with either DCB or second-generation DES were included in the analysis. The composite primary end point was all-cause mortality or myocardial infarction (MI) at 1 year. Secondary end points included each component of the primary end point. The safety end point was defined by hospitalization due to bleeding events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 1-year follow-up, the primary outcome occurred in 10.4% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009206) of the DCB group versus 12.9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009254) of the DES group (HR, 0.77; 95% CI, 0.64\u20130.93). Among secondary outcomes, all-cause mortality was lower in the DCB group (6.3%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009125) compared to the DES group (8.1%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009160; HR, 0.75; 95% CI, 0.59\u20130.94), as was hospitalization for bleeding (2.5%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950 vs. 4.2%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200982; HR, 0.65; 95% CI, 0.45\u20130.96). Rates of MI were similar between groups (HR, 0.83; 95% CI, 0.63\u20131.10).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DCBs were associated with lower rates of the primary end point all-cause death or myocardial infarction, as well as secondary end points all-cause death and bleeding compared with second-generation DES. These findings suggest that DCBs may represent a safe and effective alternative to DES in selected patient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02781-7","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:27:54Z","timestamp":1764055674000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes of drug-coated balloon vs. second-generation drug-eluting stent for coronary in-stent restenosis"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-0954","authenticated-orcid":false,"given":"J.","family":"Krefting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Friess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gr\u00e4\u00dfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Starnecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kufner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. B.","family":"Sager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Xhepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Offenborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Dreischulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Giacoppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cassese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"von Scheidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4170-7347","authenticated-orcid":false,"given":"J.","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2781_CR1","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.4244\/EIJV17I5A60","volume":"17","author":"F Alfonso","year":"2021","unstructured":"Alfonso F, Kastrati A (2021) Clinical burden and implications of coronary interventions for in-stent restenosis. EuroIntervention 17:e355\u2013e357","journal-title":"EuroIntervention"},{"key":"2781_CR2","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jacc.2020.08.002","volume":"76","author":"ID Moussa","year":"2020","unstructured":"Moussa ID, Mohananey D, Saucedo J, Stone GW, Yeh RW, Kennedy KF, Waksman R, Teirstein P, Moses JW, Simonton C (2020) Trends and outcomes of restenosis after coronary stent implantation in the United States. J Am Coll Cardiol 76:1521\u20131531","journal-title":"J Am Coll Cardiol"},{"key":"2781_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"F-J Neumann","year":"2019","unstructured":"Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, J\u00fcni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO (2019) 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J 40:87\u2013165","journal-title":"Eur Heart J"},{"key":"2781_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jacc.2022.05.017","volume":"80","author":"G Giustino","year":"2022","unstructured":"Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R, Stone GW, Kini A, Sharma SK (2022) Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol 80:348\u2013372","journal-title":"J Am Coll Cardiol"},{"key":"2781_CR5","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1016\/j.jacc.2020.04.006","volume":"75","author":"D Giacoppo","year":"2020","unstructured":"Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, P\u00e9rez-Vizcayno MJ, Kang D-Y, Degenhardt R, Pleva L, Baan J, Cuesta J, Park D-W, Kukla P, Jim\u00e9nez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park S-J, Henriques JPS, Kastrati A, Byrne RA (2020) Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol 75:2664\u20132678","journal-title":"J Am Coll Cardiol"},{"key":"2781_CR6","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, ten Berg JM, van Belle E, van Craenenbroeck EM, Vidal-Perez R, Winther S (2024) 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 45:3415\u20133537","journal-title":"Eur Heart J"},{"key":"2781_CR7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.jacc.2012.01.015","volume":"59","author":"H Rittger","year":"2012","unstructured":"Rittger H, Brachmann J, Sinha A-M, Waliszewski M, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Breithardt O-A, Schmidt M, Zimmermann S, Lonke S, von Cranach M, Nguyen T-V, Daniel WG, W\u00f6hrle J (2012) A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 59:1377\u20131382","journal-title":"J Am Coll Cardiol"},{"key":"2781_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(12)61964-3","volume":"381","author":"RA Byrne","year":"2013","unstructured":"Byrne RA, Neumann F-J, Mehilli J, Pinieck S, Wolff B, Tiroch K, Schulz S, Fusaro M, Ott I, Ibrahim T, Hausleiter J, Valina C, Pache J, Laugwitz K-L, Massberg S, Kastrati A (2013) Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 381:461\u2013467","journal-title":"Lancet"},{"key":"2781_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jama.2024.1361","volume":"331","author":"RW Yeh","year":"2024","unstructured":"Yeh RW, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, Stoler R, Jefferson BK, Nicholson W, Altman J, Bateman C, Krishnaswamy A, Grantham JA, Zidar FJ, Marso SP, Tremmel JA, Grines C, Ahmed MI, Latib A, Tehrani B, Abbott JD, Batchelor W, Underwood P, Allocco DJ, Kirtane AJ (2024) Paclitaxel-coated balloon vs uncoated balloon for coronary in-stent restenosis: the AGENT IDE randomized clinical trial. JAMA 331:1015\u20131024","journal-title":"JAMA"},{"key":"2781_CR10","unstructured":"U.S. Food & Drug Administration. AGENT paclitaxel-coated balloon catheter \u2013 P230035. 2024. https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/agent-paclitaxel-coated-balloon-catheter-p230035. Accessed 12 Mar 2024"},{"key":"2781_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/eurheartj\/ehad026","volume":"44","author":"D Giacoppo","year":"2023","unstructured":"Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, Wiebe J, Joner M, Hochholzer W, Laugwitz K-L, Schunkert H, Kastrati A, Kufner S (2023) Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J 44:1343\u20131357","journal-title":"Eur Heart J"},{"key":"2781_CR12","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1093\/eurheartj\/ehz594","volume":"41","author":"D Giacoppo","year":"2020","unstructured":"Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, P\u00e9rez-Vizcayno MJ, Kang D-Y, Degenhardt R, Pleva L, Baan J, Cuesta J, Park D-W, Schunkert H, Colleran R, Kukla P, Jim\u00e9nez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park S-J, Henriques JPS, Kastrati A, Byrne RA (2020) Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J 41:3715\u20133728","journal-title":"Eur Heart J"},{"key":"2781_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jcin.2018.02.037","volume":"11","author":"F Alfonso","year":"2018","unstructured":"Alfonso F, P\u00e9rez-Vizcayno MJ, Cuesta J, Del Garc\u00eda BB, Garc\u00eda-Touchard A, L\u00f3pez-M\u00ednguez JR, Masotti M, Zueco J, Cequier A, Vel\u00e1zquez M, Moreno R, Mainar V, Dom\u00ednguez A, Moris C, Molina E, Rivero F, Jim\u00e9nez-Quevedo P, Gonzalo N, Fern\u00e1ndez-P\u00e9rez C (2018) 3-year clinical follow-up of the RIBS IV clinical trial: a prospective randomized study of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis in coronary arteries previously treated with drug-eluting stents. JACC Cardiovasc Interv 11:981\u2013991","journal-title":"JACC Cardiovasc Interv"},{"key":"2781_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.jcin.2015.04.032","volume":"8","author":"H Kawamoto","year":"2015","unstructured":"Kawamoto H, Ruparelia N, Latib A, Miyazaki T, Sato K, Mangieri A, Contri R, Stella S, Figini F, Chieffo A, Carlino M, Montorfano M, Colombo A (2015) Drug-coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetal-layered in-stent restenosis. JACC Cardiovasc Interv 8:1586\u20131594","journal-title":"JACC Cardiovasc Interv"},{"key":"2781_CR15","doi-asserted-by":"crossref","unstructured":"Krefting J, Graesser C, Novacek S, Voll F, Moggio A, Krueger N, Friess C, Schwab M, Offenborn F, Trenkwalder T, Kufner S, Xhepa E, Joner M, Cassese S, Schunkert H, Ndrepepa G, Kastrati A, Scheidt M von, Kessler T, Sager HB (2025) Sex-specific outcomes in myocardial infarction: a dual-cohort analysis using clinical and real-world data. Clin Res Cardiol","DOI":"10.1007\/s00392-025-02627-2"},{"key":"2781_CR16","unstructured":"Federal_Institue_for_Drugs_and_Medical_Devices (2021) Observational bavarian health insurance registry. https:\/\/drks.de\/search\/en\/trial\/DRKS00024016. Accessed\u202f17 Dec 2024"},{"key":"2781_CR17","doi-asserted-by":"publisher","first-page":"e2448389","DOI":"10.1001\/jamanetworkopen.2024.48389","volume":"7","author":"N Kr\u00fcger","year":"2024","unstructured":"Kr\u00fcger N, Krefting J, Kessler T, Schmieder R, Starnecker F, Dutsch A, Graesser C, Meyer-Lindemann U, Storz T, Pugach I, Frie\u00df C, Chen Z, Bongiovanni D, Manea I, Dreischulte T, Offenborn F, Krase P, Sager HB, Wiebe J, Kufner S, Xhepa E, Joner M, Trenkwalder T, Gueldener U, Kastrati A, Cassese S, Schunkert H, von Scheidt M (2024) Ticagrelor vs prasugrel for acute coronary syndrome in routine care. JAMA Netw Open 7:e2448389","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2781_CR18","doi-asserted-by":"publisher","first-page":"11349","DOI":"10.4088\/JCP.20f13681","volume":"81","author":"C Andrade","year":"2020","unstructured":"Andrade C (2020) Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry 81(5):11349","journal-title":"J Clin Psychiatry"},{"key":"2781_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0140-6736(15)60657-2","volume":"386","author":"GCM Siontis","year":"2015","unstructured":"Siontis GCM, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, P\u00e9rez-Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, J\u00fcni P, Windecker S (2015) Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 386:655\u2013664","journal-title":"Lancet"},{"key":"2781_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ahj.2017.11.008","volume":"197","author":"YTA Wong","year":"2018","unstructured":"Wong YTA, Kang D-Y, Lee JB, Rha S-W, Hong YJ, Shin E-S, Her S-H, Nam CW, Chung W-Y, Kim MH, Lee CH, Lee PH, Ahn J-M, Kang S-J, Lee S-W, Kim Y-H, Lee CW, Park S-W, Park D-W, Park S-J (2018) Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: a randomized RESTORE trial. Am Heart J 197:35\u201342","journal-title":"Am Heart J"},{"key":"2781_CR21","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.4244\/EIJ-D-17-01079","volume":"14","author":"CJ Jensen","year":"2018","unstructured":"Jensen CJ, Richardt G, T\u00f6lg R, Erglis A, Skurk C, Jung W, Neumann FJ, Stangl K, Brachmann J, Fischer D, Mehilli J, Rieber J, Wiemer M, Schofer J, Sack S, Naber CK (2018) Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. EuroIntervention 14:1096\u20131103","journal-title":"EuroIntervention"},{"key":"2781_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jcin.2017.10.024","volume":"11","author":"J Baan","year":"2018","unstructured":"Baan J, Claessen BE, Dijk KB, Vendrik J, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, de Winter RJ, Koch KT, Sjauw KD, Beijk MA, Vis MM, Wykrzykowska JJ, Piek JJ, Tijssen JGP, Henriques JPS (2018) A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the DARE trial. JACC Cardiovasc Interv 11:275\u2013283","journal-title":"JACC Cardiovasc Interv"},{"key":"2781_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MCA.0000000000000784","volume":"30","author":"G Wang","year":"2019","unstructured":"Wang G, Zhao Q, Chen Q, Zhang X, Tian L, Zhang X (2019) Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis. Coron Artery Dis 30:473\u2013480","journal-title":"Coron Artery Dis"},{"key":"2781_CR24","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jacc.2009.04.082","volume":"54","author":"F Alfonso","year":"2009","unstructured":"Alfonso F, Garc\u00eda J, P\u00e9rez-Vizcayno M-J, Hernando L, Hernandez R, Escaned J, Jim\u00e9nez-Quevedo P, Ba\u00f1uelos C, Macaya C (2009) New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. J Am Coll Cardiol 54:1036\u20131038","journal-title":"J Am Coll Cardiol"},{"key":"2781_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, J\u00fcni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F-J, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213\u2013260","journal-title":"Eur Heart J"},{"key":"2781_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58:323\u2013337","journal-title":"J Clin Epidemiol"},{"key":"2781_CR27","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.4244\/EIJ-D-20-00662","volume":"17","author":"E Xhepa","year":"2021","unstructured":"Xhepa E, Bresha J, Joner M, Hapfelmeier A, Rivero F, Ndrepepa G, Nano N, Cuesta J, Kufner S, Cassese S, Bastante T, Aytekin A, Rroku A, Garc\u00eda-Guimaraes M, Lahmann AL, Pinieck S, Rai H, Fusaro M, Schunkert H, P\u00e9rez-Vizcayno MJ, Gonzalo N, Alfonso F, Kastrati A (2021) Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. EuroIntervention 17:e388\u2013e395","journal-title":"EuroIntervention"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02781-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02781-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02781-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:33:32Z","timestamp":1767864812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02781-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2781"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02781-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.K., C.F., R.S., F.S., M.S., T.T., F.V., E.X., F.O., T.D., D.G., S.C., and J.W. report no disclosuresN.K. reported receiving grants from the German Heart Foundation and the Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung outside the submitted work. M.v.S. has been supported by an excellence grant of the German Center for Cardiovascular Research (DZHK-81X3600506) and is also funded by the Corona Foundation as part of the Junior Research Group Somatic Mutations (S199\/10085\/2021). M.v.S. and H.S. have received funding from the European Union (HORIZON) for the Multiomics based Risk stratification of Atherosclerotic CardiovascuLar disEase project (MIRACLE: 101115381). H.B.S. has received funding from the European Research Council under the European Union\u2019s Horizon 2020 Research and Innovation Programme (STRATO, grant agreement No. 759272), the \u201cElse-Kr\u00f6ner-Fresenius-Stiftung\u201d (2020_EKSE.07), and the \u201cDeutsche Forschungsgemeinschaft (DFG)\u201d (515567441, 470462396, and CRC 1123 (B11)). T.K.\u2019s work is funded by the European Union (ERC, MATRICARD, 101077205; to T.K.). Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. T.K.\u2019s work is also funded by the Corona Foundation as part of the Junior Research Group Translational Cardiovascular Genomics (S199\/10070\/2017) and the German Research Foundation (DFG) as part of the collaborative research center SFB 1123 (B2, to T.K. and H.S.), the research project KE 2116\/4\u20131), and the Heisenberg Program (KE 2116\/5\u20131). C.G. has been supported by an excellence grant of the German Center for Cardiovascular Research (FKZ-81X3600511). H.B.S. received lecture fees and travel support from Novo Nordisk Pharma GmbH, AstraZeneca GmbH, Translumina, and Abbott Medical GmbH. H.S., A.K., and T.K. are named inventors on a patent application for prevention of restenosis after angioplasty and stent implantation outside the submitted work. T.K. received lecture fees from Translumina, Bristol-Myers Squibb, Abbott, and Astra-Zeneca, which are unrelated to this work. S.K. reports speaker and consulting fees from AstraZeneca, Bristol Myers Squibb, and Bentley, speaker fees from Abbott, Boehringer-Ingelheim, and Translumina, and a research grant from Bentley, not related to the current work","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}